Recent Updates
Recently added Catalysts
TSHA Positive Sentiment

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

Monday, August 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Taysha Gene Therapies has expanded its strategic partnership with Catalent to include future commercial manufacturing support for its TSHA-102 gene therapy, aimed at treating Rett Syndrome. This collaboration is expected to enhance Taysha's capabilities in bringing their gene therapy to market. The partnership signifies a commitment to advancing treatments for rare diseases.
Price reaction · baseline $5.86 (2026-07-31 close) · hit pre-market · clean, no other TSHA news in the window
day 0 close · peak
-1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Expansion of partnership enhances manufacturing capabilities.
  • Support for TSHA-102 gene therapy could accelerate development.
  • Collaboration with Catalent brings expertise in commercial manufacturing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+67%
120-day peak, hindsight
Typical move
1.7%
average across 4 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
TSHA-101
Phase 1 · Infantile GM2 Gangliosidosis (Disorder)

Full Press Release Details

CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous

Frequently Asked Questions

What is TSHA-102?

TSHA-102 is a gene therapy developed by Taysha Gene Therapies for treating Rett Syndrome.

Who is partnering with Taysha Gene Therapies?

Taysha is partnering with Catalent to support the commercial manufacturing of TSHA-102.

What is the focus of Taysha Gene Therapies?

Taysha focuses on developing AAV-based gene therapies for rare, monogenic diseases.

When was the partnership expansion announced?

The expansion of the partnership was announced on August 3, 2026.

ShareAdd on Google
Tags: TSHA Viatris Investor Conferences Healthcare Taysha Gene Therapies Catalent TSHA-102 Rett Syndrome gene therapy
Last updated: Aug 3, 2026

Biotech snapshot

Cash runway
$277M liquidity · $14M/mo burn
~18 mo
Low dilution risk
Lead asset
TSHA-101Phase 1
Infantile GM2 Gangliosidosis (Disorder) →

Catalyst track record

+67%
best trade around TSHA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for TSHA.

See every catalyst's timing & PoA →